Advertisement

International Journal of Clinical Pharmacy

, Volume 37, Issue 6, pp 1104–1110 | Cite as

Knowledge and attitude of health-care professionals in hospitals towards pharmacovigilance in Saudi Arabia

  • Thamir M. AlshammariEmail author
  • Khaled K. Alamri
  • Yazeed A. Ghawa
  • Noura F. Alohali
  • Shaza A. Abualkol
  • Hisham S. Aljadhey
Research Article

Abstract

Background Drug safety has major implications for patients’ lives. However, this concept is still considered new to some healthcare professionals. Objective This study aims to investigate the knowledge and awareness of Saudi healthcare professionals to pharmacovigilance (PV). Setting Governmental and private hospitals at three main cities in Saudi Arabia (Riyadh, Jeddah, and Dammam). Methods A cross-sectional survey among healthcare professionals (pharmacists, physicians, and nurses) within 12 Saudi hospitals was conducted between November and December 2012. The questionnaire consisted of 18 questions assessing the knowledge, awareness, and attitude of healthcare professionals (HCPs) towards science and the concept of PV. Descriptive statistics were used to analyze the data. The data were analyzed using Statistical Analysis Software (SAS 9.3). Main outcome measure Knowledge, attitude and practice of HCPs toward pharmacovigilance. Results Three-hundred and thirty-two healthcare professionals completed the survey (response rate 72 %), 110 (34 %) physicians, 106 (33 %) pharmacists, and 104 (32 %) nurses. More than half of the participants (55 %) did not know the correct definition of PV. Two-thirds of the respondents, 207 (65.5 %), had knowledge of the aim of post-marketing surveillance, yet only 113 (36.9 %) were aware that the National Pharmacovigilance and Drug Safety Center is the official body for monitoring adverse drug reaction in Saudi Arabia. In addition, 34.7 % agreed that lack of time could be a major barrier for reporting. The majority of the respondents (78.4 %) believed that reporting was a professional obligation and hospitals should have a drug safety department. Conclusions There was a limited knowledge of pharmacovigilance that could have affected reporting incidence. Educational intervention and a practical training program need to be applied by the drug regulatory body as well as health authorities to enhance the pharmacovigilance and drug safety culture in Saudi Arabia.

Keywords

Healthcare professional Hospital Knowledge and attitude Pharmacovigilance Saudi Arabia 

Notes

Acknowledgments

The authors would like to thank all the health-care professionals who participated in our study.

Funding

The study was not funded.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Supplementary material

11096_2015_165_MOESM1_ESM.doc (94 kb)
Supplementary material 1 (DOC 95 kb)

References

  1. 1.
    WHO. Importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/EMP_ConsumerReporting_web_v2.pdf. 2002. Accessed 10 Feb 2013.
  2. 2.
    van Grootheest AC, de Jong-van den Berg LT. The role of hospital and community pharmacists in pharmacovigilance. Res Social Adm Pharm. 2005;1:126–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Keers RN, Williams SD, Cooke J, Ashcroft DM. Causes of medication administration errors in hospitals: a systematic review of quantitative and qualitative evidence. Drug Saf. 2013;36:1045–67.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Kripalani S, Roumie CL, Dalal AK, Cawthon C, Businger A, Eden SK, et al. Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial. Ann Intern Med. 2012;157:1–10.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Davis P, Lay-Yee R, Briant R, Ali W, Scott A, Schug S. Adverse events in New Zealand public hospitals I: occurrence and impact. N Z Med J. 2002;115:U271.PubMedGoogle Scholar
  7. 7.
    Wilson RM, Runciman WB, Gibberd RW, Harrison BT, Newby L, Hamilton JD. The quality in Australian Health Care Study. Med J Aust. 1995;163:458–71.PubMedGoogle Scholar
  8. 8.
    Vincent C, Neale G, Woloshynowych M. Adverse events in British hospitals: preliminary retrospective record review. BMJ. 2001;322:517–9.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Aljadhey H, Mahmoud MA, Mayet A, Alshaikh M, Ahmed Y, Murray MD, et al. Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Health Care. 2013;25:648–55.CrossRefPubMedGoogle Scholar
  10. 10.
    Ahmad A, Patel I, Balkrishnan R, Mohanta GP, Manna PK. An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: a pilot study. Perspect Clin Res. 2013;4:204–10.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Agarwal R, Daher AM, Mohd Ismail N. Knowledge, practices and attitudes towards adverse drug reaction reporting by private practitioners from Klang Valley in Malaysia. Malays J Med Sci. 2013;20:52–61.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Palaian S, Ibrahim MI, Mishra P. Health professionals’ knowledge, attitude and practices towards pharmacovigilance in Nepal. Pharm Pract (Granada). 2011;9:228–35.CrossRefGoogle Scholar
  13. 13.
    Oreagba IA, Ogunleye OJ, Olayemi SO. The knowledge, perceptions and practice of pharmacovigilance amongst community pharmacists in Lagos state, south west Nigeria. Pharmacoepidemiol Drug Saf. 2011;20:30–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Amrita P, Kharbanda B. Knowledge, attitude and skills of nurses of Delhi towards adverse drug reaction reporting. Indian J Pharm Pract. 2012;5:45–51.Google Scholar
  15. 15.
    UPPSALA REPORTS. World Health Organization. http://who-umc.org/graphics/24355.pdf. 2009. Accessed 10 Feb 2013.
  16. 16.
    Saudi Arabia Experience. The first Arab/EMR meeting of Pharmacovigilance. WHO Collaborating Centre for Pharmacovigilance in collaboration with the World Health Organization (WHO). 22–27, Sept 2014. http://www.capm.ma/Doc/Workshop/RAPV/Saudi%20Arabia%20PV%20centre.pdf. 2014. Accessed 02 Dec 2014.
  17. 17.
    Aljadhey H, Alhusan A, Alburikan K, Adam M, Murray MD, Bates DW. Medication safety practices in hospitals: a national survey in Saudi Arabia. Saudi Pharm J. 2013;21:159–64.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Khan LM, Al-Harthi SE, Saadah OI. Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharm J. 2013;21:261–6.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Ministry of Health. The Ministry. Statistics book. http://www.moh.gov.sa/en/Ministry/Statistics/book/Documents/Statistics-Book-1434.pdf. 2014. Accessed 02 Dec 2014.
  20. 20.
    Rajesh R, Vidyasagar S, Varma DM. An educational intervention to assess knowledge attitude practice of pharmacovigilance among health care professionals in an Indian tertiary care teaching hospital. Int J Pharm Tech Res. 2011;3(2):678–92.Google Scholar
  21. 21.
    Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32:19–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Hardeep, Bajaj JK, Rakesh K. A survey on the knowledge, attitude and the practice of pharmacovigilance among the health care professionals in a teaching hospital in northern India. J Clin Diagn Res. 2013;7:97–9.Google Scholar
  23. 23.
    Li Q, Zeng F. Awareness and attitude of healthcare professionals in Wuhan, China to the reporting of adverse drug reactions. Chin Med J. 2004;117:856–61.PubMedGoogle Scholar
  24. 24.
    Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, et al. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals. Drug Saf. 2012;35:845–54.CrossRefPubMedGoogle Scholar
  25. 25.
    Pirmohamed M, Atuah KN, Dodoo AN, Winstanley P. Pharmacovigilance in developing countries. BMJ. 2007;335:462.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol. 1995;39:223–6.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group. Eur J Clin Pharmacol. 1997;52:423–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Eland IA, Belton KJ, van Grootheest AC, Meiners AP, Rawlins MD, Stricker BH. Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol. 1999;48:623–7.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Fadare J, Enwere O, Afolabi A, Chedi B, Musa A. Knowledge, attitude and practice of adverse drug reaction reporting among healthcare workers in a Tertiary Centre in Northern Nigeria. Trop J Pharm Res. 2011;10:235–42.CrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015

Authors and Affiliations

  • Thamir M. Alshammari
    • 1
    • 2
    Email author
  • Khaled K. Alamri
    • 3
  • Yazeed A. Ghawa
    • 3
  • Noura F. Alohali
    • 3
  • Shaza A. Abualkol
    • 1
  • Hisham S. Aljadhey
    • 2
    • 3
  1. 1.College of PharmacyUniversity of HailHailSaudi Arabia
  2. 2.Medication Safety Research ChairKing Saud UniversityRiyadhSaudi Arabia
  3. 3.College of PharmacyKing Saud UniversityRiyadhSaudi Arabia

Personalised recommendations